By Max Breet
Biological risks have become a strategic feature of global life but for Britain the central question is one of pace: whether the country can apply its scientific and industrial strengths quickly enough to stay ahead of rapidly evolving biological signals. The stakes are significant but so is the opportunity. If the UK…
Max Breet
Max Breet is Director - EMEA Business Development at Ginkgo Bioworks, Inc and manages key regional relationships, drives growth across EMEA governments for their Biosecurity business and specifically oversees operational work in the UK, Qatar and Ukraine. Previously, Max led European Mission Operations at Anduril Industries, Inc and started his career as a Royal Marines Commando, serving in multiple leadership roles across 3 Commando Brigade, before focusing on product management in optics, robotics and autonomy in the latter stage of his military service. He is currently based in London, UK.
1 article published